Metabolomics During Testosterone Therapy
Completed
Conditions studied: Testosterone Deficiency
In brief
One promising but understudied area in the field of testosterone (T) therapy is its effect on metabolism and the development of type II diabetes. Metabolomics is a powerful research tool that can detect very early signs of metabolic derangement that may lead to metabolic disease. In this observational study, investigators aim to apply metabolomics in order to better understand how T therapy influences metabolism. In a clinical population of outpatient men with T deficiency investigators will perform comprehensive clinical evaluations and also obtain blood for metabolomics. This will be done once prior to T therapy and again after 4-6 months of T therapy. Investigators hypothesize that they can detect metabolic derangements in men with T deficiency and that these derangements will improve with T therapy.
Key facts
- Study ID
- NCT01963390
- Run by
- Men's Health Boston
- People needed
- 60
- Starts
- 2012-07-01
- Expected to finish
- 2017-12-01
- Last updated by the study team
- 2018-04-19
Who can join
Age: 20 and older, up to 90. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Symptomatic testosterone deficiency
- Intend to undergo testosterone therapy at Men's Health Boston
- Total testosterone <350ng/dL or free testosterone <1.5ng/dL
You may not qualify if…
- Type 1 diabetes
- Use of exogenous testosterone or clomiphene citrate
- Known karyotype abnormalities
- Seizure disorders
- Malignancy
Where it is running
- Men's Health Boston — Chestnut Hill, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.